Clinical applications of botulinum toxinDRESSLER, Dirk.Current opinion in microbiology. 2012, Vol 15, Num 3, pp 325-336, issn 1369-5274, 12 p.Article

Clinical features of antibody-induced complete secondary failure of botulinum toxin therapyDRESSLER, Dirk.European neurology. 2002, Vol 48, Num 1, pp 26-29, issn 0014-3022Article

Botulinum toxin : Mechanisms of actionDRESSLER, Dirk; ADIB SABERI, Fereshte.European neurology. 2005, Vol 53, Num 1, pp 3-9, issn 0014-3022, 7 p.Article

Botulinum toxin type B de novo therapy of cervical dystonia : Frequency of antibody induced therapy failureDRESSLER, Dirk; BIGALKE, Hans.Journal of neurology. 2005, Vol 252, Num 8, pp 904-907, issn 0340-5354, 4 p.Article

Diagnosis and management of acute movement disordersDRESSLER, Dirk; BENECKE, Reiner.Journal of neurology. 2005, Vol 252, Num 11, pp 1299-1306, issn 0340-5354, 8 p.Article

Botulinum toxin antibody type A titres after cessation of botulinum toxin therapyDRESSLER, Dirk; BIGALKE, Hans.Movement disorders. 2002, Vol 17, Num 1, pp 170-173, issn 0885-3185Article

Antibody-induced failure of botulinum toxin type B therapy in de novo patientsDRESSLER, Dirk; BIOALKE, Hans.European neurology. 2004, Vol 52, Num 3, pp 132-135, issn 0014-3022, 4 p.Article

Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosisDRESSLER, Dirk; BENECKE, Reiner.European neurology. 2003, Vol 49, Num 1, pp 34-38, issn 0014-3022, 5 p.Article

Mouse diaphragm assay for detection of antibodies against botulinum toxin type BDRESSLER, Dirk; LANGE, M; BIGALKE, Hans et al.Movement disorders. 2005, Vol 20, Num 12, pp 1617-1619, issn 0885-3185, 3 p.Article

Treatment of cervical dystonia with botulinum toxinJANKOVIC, Joseph.Movement disorders. 2004, Vol 19, pp 109-115, issn 0885-3185, 7 p., SUP8Conference Paper

Clinical presentation and management of antibody-induced failure of botulinum toxin therapyDRESSIER, Dirk.Movement disorders. 2004, Vol 19, pp 92-100, issn 0885-3185, 9 p., SUP8Conference Paper

Basic and Therapeutic Aspects of NeurotoxinsBIGALKE, HANS; DRESSLER, Dirk; JANKOVIC, Joseph et al.Movement disorders. 2004, Vol 19, issn 0885-3185, 169 p., SUP8Conference Proceedings

Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure?DRESSLER, Dirk; ZETTL, Uwe; BENECKE, Reiner et al.Movement disorders. 2000, Vol 15, Num 6, pp 1279-1281, issn 0885-3185Article

Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's diseaseWALTER, Uwe; DRESSLER, Dirk; WOLTERS, Alexander et al.Movement disorders. 2007, Vol 22, Num 1, pp 48-54, issn 0885-3185, 7 p.Article

Botulinum toxin treatment of occupational and focal hand dystoniaKARP, Barbara Illowsky.Movement disorders. 2004, Vol 19, pp 116-119, issn 0885-3185, 4 p., SUP8Conference Paper

Use of botulinum toxin in pediatric spasticity (cerebral palsy)BERWECK, Steffen; HEINEN, Florian.Movement disorders. 2004, Vol 19, pp 162-167, issn 0885-3185, 6 p., SUP8Conference Paper

BotDB: A database resource for the clostridial neurotoxinsLEBEDA, Frank J.Movement disorders. 2004, Vol 19, pp 35-41, issn 0885-3185, 7 p., SUP8Conference Paper

Deciphering antibody properties that lead to potent botulinum neurotoxin neutralizationMARKS, James D.Movement disorders. 2004, Vol 19, pp 101-108, issn 0885-3185, 8 p., SUP8Conference Paper

Intratympanic application of botulinum toxin : experiments in guinea pigs for excluding ototoxic effectsZEHLICKE, Thorsten; PUNKE, Christoph; DRESSLER, Dirk et al.European archives of oto-rhino-laryngology. 2008, Vol 265, Num 2, pp 167-170, issn 0937-4477, 4 p.Article

Botulinum toxin treatment of secretory disordersNAUMANN, Markus; JOST, Wolfgang.Movement disorders. 2004, Vol 19, pp 137-141, issn 0885-3185, 5 p., SUP8Conference Paper

Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxinERBGUTH, Frank J.Movement disorders. 2004, Vol 19, pp 2-6, issn 0885-3185, 5 p., SUP8Conference Paper

Basic immunological aspects of botulinum toxin therapyZOUHAIR ATASSI, M.Movement disorders. 2004, Vol 19, pp 68-84, issn 0885-3185, 17 p., SUP8Conference Paper

Physiological effects of botulinum toxin in spasticityGRACIES, Jean-Michel.Movement disorders. 2004, Vol 19, pp 120-128, issn 0885-3185, 9 p., SUP8Conference Paper

Absence of congruency sequence effects reveals neurocognitive inflexibility in Parkinson's diseaseRUSTAMOV, Nabi; RODRIGUEZ-RAECKE, Rea; KOPP, Bruno et al.Neuropsychologia. 2013, Vol 51, Num 14, pp 2976-2987, issn 0028-3932, 12 p.Article

Mutation at the SCA17 locus is not a common cause of primary dystoniaGRUNDMANN, Kathrin; LAUBIS-HERRMANN, Ulrike; DRESSLER, Dirk et al.Journal of neurology. 2004, Vol 251, Num 10, pp 1232-1234, issn 0340-5354, 3 p.Article